These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 6788372

  • 1. Phase II study of cyclophosphamide and hexamethylmelamine in non-oat cell bronchogenic carcinoma.
    Pisoni MB, Libretti A, Piazza E, Vago G, Scapaticci R, Bianchi C, Tomirotti M, Scanni A, Calzavara MP, Cassani L, Scarpazza G, Marsoni S, Morasca L.
    Cancer Treat Rep; 1981; 65(7-8):731-2. PubMed ID: 6788372
    [No Abstract] [Full Text] [Related]

  • 2. Six-drug combination chemotherapy for nonresectable bronchogenic carcinoma.
    Miller CF, Weltz MD, Heim WJ, Blom J.
    Cancer Treat Rep; 1979 Aug; 63(8):1351-3. PubMed ID: 113094
    [No Abstract] [Full Text] [Related]

  • 3. Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer.
    Sessa C, D'Incalci M, Valente I, Bolis G, Colombo N, Mangioni C.
    Cancer Treat Rep; 1982 May; 66(5):1233-4. PubMed ID: 6805951
    [No Abstract] [Full Text] [Related]

  • 4. Hexamethylmelamine, doxorubicin, and cyclophosphamide in advanced ovarian cancer resistant to previous chemotherapy.
    Sessa C, Bolis G, Valente I, Mangioni C, D'Incalci M.
    Cancer Treat Rep; 1981 May; 65(1-2):172-3. PubMed ID: 6784922
    [No Abstract] [Full Text] [Related]

  • 5. Combination chemotherapy for advanced ovarian cancer: a prospective randomized trial comparing hexamethylmelamine and cyclophosphamide to doxorubicin and cyclophosphamide.
    Schwartz PE, Lawrence R, Katz M.
    Cancer Treat Rep; 1981 May; 65(1-2):137-41. PubMed ID: 6261948
    [Abstract] [Full Text] [Related]

  • 6. Lessons from a time capsule: evolution, not revolution, in therapy for advanced non-small-cell lung cancer.
    Green MR.
    J Clin Oncol; 2008 Jul 01; 26(19):3112-3. PubMed ID: 18591551
    [No Abstract] [Full Text] [Related]

  • 7. [Trials of synchronized attack drug therapy in bronchogenic carcinoma].
    Seccia A, Scafuri L, Scognamillo A, Cocco G.
    G Ital Chemioter; 1975 Jul 01; 22(1-2):63-6. PubMed ID: 1235355
    [No Abstract] [Full Text] [Related]

  • 8. Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP) treatment of non-oat cell bronchogenic carcinoma.
    Vogelzang NJ, Bonomi PD, Rossof AH, Wolter J.
    Cancer Treat Rep; 1978 Oct 01; 62(10):1595-7. PubMed ID: 709563
    [No Abstract] [Full Text] [Related]

  • 9. Hexamethylmelamine in inoperable bronchogenic carcinoma.
    Takita H.
    N Y State J Med; 1972 Feb 15; 72(4):477-80. PubMed ID: 4334448
    [No Abstract] [Full Text] [Related]

  • 10. Chemotherapy for metastatic non-small cell bronchogenic carcinoma: EST 2575, generation III, HAM versus CAMP.
    Ruckdeschel JC, Mehta CR, Salazar OM, Creech RH, Sponzo RW.
    Cancer Treat Rep; 1981 Feb 15; 65(11-12):959-63. PubMed ID: 6794909
    [Abstract] [Full Text] [Related]

  • 11. Cisplatin combination chemotherapy in non-oat cell carcinoma of the lung.
    Vincent RG, Lane WW, Raza S, Madajewicz S.
    Cancer Treat Rep; 1982 Jan 15; 66(1):197-8. PubMed ID: 6975658
    [No Abstract] [Full Text] [Related]

  • 12. Single-agent adriamycin followed by combination hexamethylmelamine-cyclophosphamide for advanced ovarian carcinoma.
    Wharton JT, Herson J, Edwards CL, Griffith AB.
    Gynecol Oncol; 1982 Oct 15; 14(2):262-70. PubMed ID: 6813202
    [No Abstract] [Full Text] [Related]

  • 13. Ifosfamide: a weekly dose fractionated schedule in bronchogenic carcinoma.
    Morgan LR, Posey LE, Rainey J, Bickers J, Ryan D, Vial R, Hull EW.
    Cancer Treat Rep; 1981 Oct 15; 65(7-8):693-5. PubMed ID: 6265084
    [No Abstract] [Full Text] [Related]

  • 14. Combination chemotherapy with CCNU (NSC-79037),hexamethylmelamine (NSC-13875) and methotrexate (NSC-740) in advanced bronchogenic carcinoma.
    DiBella NJ, Nelson RA, Norgard MJ.
    Oncology; 1975 Oct 15; 32(2):82-5. PubMed ID: 815858
    [Abstract] [Full Text] [Related]

  • 15. Combination chemotherapy for bronchogenic carcinoma with doxorubicin, BCNU, and cyclophosphamide (ABC): a pilot study of the Southeastern Cancer Study Group.
    Denes AE, Presant CA, Bartolucci A.
    Cancer Treat Rep; 1982 Jan 15; 66(1):199-200. PubMed ID: 7053258
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Phase II trial of bisantrene for unresectable non-small cell bronchogenic carcinoma: an Illinois Cancer Council study.
    McGuire WP, Blough RR, Cobleigh MA, Johnson CM, Kukla LJ, Lad TE, Lanzotti VJ, Stiff PJ, Zawila P.
    Cancer Treat Rep; 1983 Sep 15; 67(9):841-2. PubMed ID: 6883363
    [No Abstract] [Full Text] [Related]

  • 18. Preliminary report on the use of CCNU (NSC-79037), adriamycin (NSC-123127), and hexamethylmelamine (NSC-13875) in carcinoma of the lung.
    Wilson WL, Andrews NC, Frelick RW, Nealon TF, Bick RL, Adams T.
    Cancer Treat Rep; 1976 Mar 15; 60(3):269-71. PubMed ID: 816467
    [No Abstract] [Full Text] [Related]

  • 19. Cyclophosphamide, doxorubicin, and cisplatin in the treatment of non-small cell bronchogenic carcinoma.
    Evans WK, Feld R, DeBoer G, Osoba D, Curtis JE, Baker MA, Myers RE, Quirt IC, Pritchard KI, Brown TC, Kutas GJ, Blackstein ME, Ottema B, Millband L.
    Cancer Treat Rep; 1981 Mar 15; 65(11-12):947-54. PubMed ID: 7028256
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.